{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:08:56Z","timestamp":1792681736637,"version":"4.5.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-025-01387-6","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:47:59Z","timestamp":1768452479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incidence, Risk Factors, and Management of Radiotherapy-Related Skin Toxicity in Rectoanal Cancer Patients: a Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"57","author":[{"given":"Yingge","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghui","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"6","key":"1387_CR1","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1053\/j.gastro.2023.08.022","volume":"165","author":"Q Qin","year":"2023","unstructured":"Qin Q, et al. Development and validation of a Post-Radiotherapy prediction model for bowel dysfunction after rectal cancer resection. Gastroenterology. 2023;165(6):1430\u2013e144214.","journal-title":"Gastroenterology"},{"issue":"6","key":"1387_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S1470-2045(25)00213-X","volume":"26","author":"A Gilbert","year":"2025","unstructured":"Gilbert A, et al. Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial. Lancet Oncol. 2025;26(6):707\u201318.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1387_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40164-025-00596-w","volume":"14","author":"H Yu","year":"2025","unstructured":"Yu H, et al. Molecular profiling of skin cells identifies distinct cellular signatures in radiation-induced skin injury across various stages in the murine dataset. Exp Hematol Oncol. 2025;14(1):18.","journal-title":"Exp Hematol Oncol"},{"issue":"12","key":"1387_CR4","first-page":"805","volume":"32","author":"F Jafari","year":"2024","unstructured":"Jafari F, et al. Topical use of Chicory root extract gel on the incidence and severity of radiodermatitis in breast cancer patients: a randomized controled trial. Support Care Cancer. 2024;32(12):805.","journal-title":"Support Care Cancer"},{"issue":"16","key":"1387_CR5","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1200\/JCO.23.02235","volume":"42","author":"NS Horowitz","year":"2024","unstructured":"Horowitz NS, et al. Phase II trial of Cisplatin, Gemcitabine, and Intensity-Modulated radiation therapy for locally advanced vulvar squamous cell carcinoma: NRG Oncology\/GOG study 279. J Clin Oncol. 2024;42(16):1914\u201321.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1387_CR6","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1001\/jamadermatol.2022.1736","volume":"158","author":"H Zhao","year":"2022","unstructured":"Zhao H, et al. Efficacy of Epigallocatechin-3-Gallate in preventing dermatitis in patients with breast cancer receiving postoperative radiotherapy: A Double-Blind, Placebo-Controlled, phase 2 randomized clinical trial. JAMA Dermatol. 2022;158(7):779\u201386.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1387_CR7","first-page":"59","volume":"122","author":"G Kalinauskaite","year":"2025","unstructured":"Kalinauskaite G, et al. Online radiotherapy: the paradigm shift to Real-Time adaptive radiotherapy. Dtsch Arztebl Int. 2025;122(3):59\u201364.","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"1387_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2468-1253(22)00392-2","volume":"8","author":"JP Gerard","year":"2023","unstructured":"Gerard JP, et al. Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2023;8(4):356\u201367.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1387_CR9","doi-asserted-by":"publisher","first-page":"m461","DOI":"10.1136\/bmj.m461","volume":"368","author":"N Bromham","year":"2020","unstructured":"Bromham N, et al. Colorectal cancer: summary of NICE guidance. BMJ. 2020;368:m461.","journal-title":"BMJ"},{"issue":"75","key":"1387_CR10","doi-asserted-by":"publisher","first-page":"954","DOI":"10.6004\/jnccn.2020.5015","volume":"18","author":"CG Willett","year":"2020","unstructured":"Willett CG. Trimodal therapy approaches for localized rectal cancer. J Natl Compr Cancer Netw J Natl Compr Canc Netw. 2020;18(75):954\u20137.","journal-title":"J Natl Compr Cancer Netw J Natl Compr Canc Netw"},{"issue":"3","key":"1387_CR11","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1470-2045(24)00032-9","volume":"25","author":"S McPhail","year":"2024","unstructured":"McPhail S, et al. Use of radiotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an international cancer benchmarking partnership (ICBP) population-based study. Lancet Oncol. 2024;25(3):352\u201365.","journal-title":"Lancet Oncol"},{"key":"1387_CR12","doi-asserted-by":"publisher","first-page":"101886","DOI":"10.1016\/j.eclinm.2023.101886","volume":"58","author":"T Behroozian","year":"2023","unstructured":"Behroozian T, et al. MASCC clinical practice guidelines for the prevention and management of acute radiation dermatitis: part 1) systematic review. EClinicalMedicine. 2023;58:101886.","journal-title":"EClinicalMedicine"},{"key":"1387_CR13","first-page":"100924","volume":"52","author":"R Serre","year":"2025","unstructured":"Serre R, et al. Brachytherapy: perspectives for combined treatments with immunotherapy. Clin Transl Radiat Oncol. 2025;52:100924.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"12","key":"1387_CR14","doi-asserted-by":"publisher","first-page":"e2030097","DOI":"10.1001\/jamanetworkopen.2020.30097","volume":"3","author":"A Kasi","year":"2020","unstructured":"Kasi A, et al. Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: a systematic review and meta-analysis. JAMA Netw Open. 2020;3(12):e2030097.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"1387_CR15","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.annonc.2022.04.010","volume":"33","author":"P Jimenez-Fonseca","year":"2022","unstructured":"Jimenez-Fonseca P, et al. Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial. Ann Oncol. 2022;33(8):786\u201393.","journal-title":"Ann Oncol"},{"issue":"10","key":"1387_CR16","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jamaoncol.2022.2831","volume":"8","author":"HF Kennecke","year":"2022","unstructured":"Kennecke HF, et al. Patterns of practice and improvements in survival among patients with stage 2\/3 rectal cancer treated with trimodality therapy. JAMA Oncol. 2022;8(10):1466\u201370.","journal-title":"JAMA Oncol"},{"issue":"4_suppl","key":"1387_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1200\/JCO.2022.40.4_suppl.094","volume":"40","author":"S Bazarbashi","year":"2022","unstructured":"Bazarbashi S, et al. Outcome of preoperative concurrent radiation and infusional gemcitabine in locally advanced rectal cancer, a phase 2 trial. J Clin Oncol. 2022;40(4_suppl):94\u201394.","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"1387_CR18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e15599","volume":"40","author":"H Yao","year":"2022","unstructured":"Yao H, et al. Safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer: short-term results of a multicenter, phase II study. J Clin Oncol. 2022;40(16_suppl):e15599-e15599.","journal-title":"J Clin Oncol"},{"issue":"36suppl","key":"1387_CR19","doi-asserted-by":"publisher","first-page":"390226","DOI":"10.1200\/JCO.2022.40.36_suppl.390226","volume":"40","author":"E Chow","year":"2022","unstructured":"Chow E, et al. Mepitel film for the prevention of acute radiation dermatitis in breast cancer: A randomized multi-centre open-label phase 3 trial. J Clin Oncol. 2022;40(36suppl):390226\u2013390226.","journal-title":"J Clin Oncol"},{"key":"1387_CR20","doi-asserted-by":"crossref","unstructured":"Tseng I et al. Radiation Dose-Volume effects on negative Tumor-Draining lymph nodes impacted T-Cell activation and prognosis in esophageal cancer with chemoradiotherapy. Clin Cancer Res, 2025.","DOI":"10.1158\/1078-0432.c.7819879"},{"issue":"16suppl","key":"1387_CR21","doi-asserted-by":"publisher","first-page":"9519","DOI":"10.1200\/JCO.2022.40.16_suppl.9519","volume":"40","author":"ND Gross","year":"2022","unstructured":"Gross ND, et al. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). J Clin Oncol. 2022;40(16suppl):9519\u20139519.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1387_CR22","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1186\/s12885-022-10226-x","volume":"22","author":"S Liu","year":"2022","unstructured":"Liu S, et al. The effect of Recombinant human epidermal growth factor on radiation dermatitis in rectal and anal cancer patients: a self-controlled study. BMC Cancer. 2022;22(1):1140.","journal-title":"BMC Cancer"},{"key":"1387_CR23","doi-asserted-by":"publisher","first-page":"798451","DOI":"10.3389\/fimmu.2021.798451","volume":"12","author":"W Xiao","year":"2021","unstructured":"Xiao W, et al. Neoadjuvant PD-1 Blockade combined with chemotherapy followed by concurrent immunoradiotherapy in locally advanced anal Canal squamous cell carcinoma patients: antitumor Efficacy, safety and biomarker analysis. Front Immunol. 2021;12:798451.","journal-title":"Front Immunol"},{"issue":"1","key":"1387_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/cam4.4433","volume":"11","author":"Y Yuan","year":"2022","unstructured":"Yuan Y, et al. Comprehensive treatment experience of anal squamous cell carcinoma from a tertiary cancer center in South China. Cancer Med. 2022;11(1):117\u201327.","journal-title":"Cancer Med"},{"key":"1387_CR25","doi-asserted-by":"publisher","first-page":"646211","DOI":"10.3389\/fonc.2021.646211","volume":"11","author":"W Huang","year":"2021","unstructured":"Huang W, et al. Effect of pelvic bone marrow sparing intensity modulated radiation therapy on acute hematologic toxicity in rectal cancer patients undergoing Chemo-Radiotherapy. Front Oncol. 2021;11:646211.","journal-title":"Front Oncol"},{"issue":"3","key":"1387_CR26","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.4143\/crt.2018.527","volume":"51","author":"J Yang","year":"2019","unstructured":"Yang J, et al. Associations of genetic variations in mismatch repair genes MSH3 and PMS1 with acute adverse events and survival in patients with rectal cancer receiving postoperative chemoradiotherapy. Cancer Res Treat. 2019;51(3):1198\u2013206.","journal-title":"Cancer Res Treat"},{"key":"1387_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1748-717X-9-113","volume":"9","author":"SA Koerber","year":"2014","unstructured":"Koerber SA, et al. Efficacy and toxicity of chemoradiation in patients with anal cancer\u2013a retrospective analysis. Radiat Oncol. 2014;9:113.","journal-title":"Radiat Oncol"},{"issue":"6","key":"1387_CR28","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/jrr\/rrad068","volume":"64","author":"X Cai","year":"2023","unstructured":"Cai X, et al. Definitive carbon ion re-irradiation with pencil beam scanning in the treatment of unresectable locally recurrent rectal cancer. J Radiat Res. 2023;64(6):933\u20139.","journal-title":"J Radiat Res"},{"key":"1387_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13014-014-0278-3","volume":"9","author":"G Cai","year":"2014","unstructured":"Cai G, et al. Accelerated hyperfractionated intensity-modulated radiotherapy for recurrent\/unresectable rectal cancer in patients with previous pelvic irradiation: results of a phase II study. Radiat Oncol. 2014;9:278.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1387_CR30","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s10350-007-9154-7","volume":"51","author":"A Wexler","year":"2008","unstructured":"Wexler A, et al. Invasive anal squamous-cell carcinoma in the HIV-positive patient: outcome in the era of highly active antiretroviral therapy. Dis Colon Rectum. 2008;51(1):73\u201381.","journal-title":"Dis Colon Rectum"},{"key":"1387_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1748-717X-5-41","volume":"5","author":"S Provencher","year":"2010","unstructured":"Provencher S, et al. Quality of life and tumor control after short split-course chemoradiation for anal Canal carcinoma. Radiat Oncol. 2010;5:41.","journal-title":"Radiat Oncol"},{"key":"1387_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15113057","author":"EB Jeans","year":"2023","unstructured":"Jeans EB, et al. Comparing oncologic outcomes and toxicity for combined modality therapy vs. carbon-ion radiotherapy for previously irradiated locally recurrent rectal cancer. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15113057.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"1387_CR33","first-page":"44","volume":"1","author":"M Bedi","year":"2007","unstructured":"Bedi M, et al. Capecitabine and timing of radiotherapy during preoperative chemoradiation for rectal cancer. Gastrointest Cancer Res. 2007;1(2):44\u20138.","journal-title":"Gastrointest Cancer Res"},{"issue":"5","key":"1387_CR34","doi-asserted-by":"publisher","first-page":"101824","DOI":"10.1016\/j.esmoop.2023.101824","volume":"8","author":"E Grassi","year":"2023","unstructured":"Grassi E, et al. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial. ESMO Open. 2023;8(5):101824.","journal-title":"ESMO Open"},{"issue":"1","key":"1387_CR35","first-page":"16","volume":"16","author":"V Picardi","year":"2017","unstructured":"Picardi V, et al. Preoperative chemoradiation with VMAT-SIB in rectal cancer: A phase II study. Clin Colorectal Cancer. 2017;16(1):16\u201322.","journal-title":"Clin Colorectal Cancer"},{"key":"1387_CR36","doi-asserted-by":"publisher","first-page":"175883592094094","DOI":"10.1177\/1758835920940945","volume":"12","author":"MS Rotundo","year":"2020","unstructured":"Rotundo MS, et al. Cisplatin plus capecitabine concomitant with intensity-modulated radiation therapy in non-metastatic anal squamous cell carcinoma: the experience of a single research cancer center. Ther Adv Med Oncol. 2020;12:1758835920940945.","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"1387_CR37","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11547-019-01007-x","volume":"124","author":"C Spatola","year":"2019","unstructured":"Spatola C, et al. Trends in combined radio-chemotherapy for locally advanced rectal cancer: a survey among radiation oncology centers of Sicily region on behalf of AIRO. Radiol Med. 2019;124(7):671\u201381.","journal-title":"Radiol Med"},{"issue":"5","key":"1387_CR38","doi-asserted-by":"publisher","first-page":"336","DOI":"10.5114\/jcb.2015.55118","volume":"7","author":"L Tagliaferri","year":"2015","unstructured":"Tagliaferri L, et al. MITHRA - multiparametric MR\/CT image adapted brachytherapy (MR\/CT-IABT) in anal Canal cancer: a feasibility study. J Contemp Brachytherapy. 2015;7(5):336\u201345.","journal-title":"J Contemp Brachytherapy"},{"issue":"5","key":"1387_CR39","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.3906\/sag-1812-185","volume":"49","author":"N Jankarashvili","year":"2019","unstructured":"Jankarashvili N, et al. Neoadjuvant volumetric modulated Arc radiochemotherapy with a simultaneous integrated boost technique compared to standard chemoradiation for locally advanced rectal cancer. Turk J Med Sci. 2019;49(5):1484\u20139.","journal-title":"Turk J Med Sci"},{"issue":"4","key":"1387_CR40","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.brachy.2013.09.006","volume":"13","author":"R Kapoor","year":"2014","unstructured":"Kapoor R, et al. Dosimetric and clinical outcome in image-based high-dose-rate interstitial brachytherapy for anal cancer. Brachytherapy. 2014;13(4):388\u201393.","journal-title":"Brachytherapy"},{"issue":"3","key":"1387_CR41","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00066-008-1731-8","volume":"184","author":"V Milani","year":"2008","unstructured":"Milani V, et al. Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. Strahlenther Onkol. 2008;184(3):163\u20138.","journal-title":"Strahlenther Onkol"},{"issue":"3","key":"1387_CR42","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejso.2009.10.002","volume":"36","author":"R Soumarova","year":"2010","unstructured":"Soumarova R, et al. Neoadjuvant chemoradiotherapy with capecitabine followed by laparoscopic resection in locally advanced tumors of middle and low rectum - toxicity and complications of the treatment. Eur J Surg Oncol. 2010;36(3):251\u20136.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"1387_CR43","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3857\/roj.2017.00353","volume":"35","author":"BK Bae","year":"2017","unstructured":"Bae BK, et al. Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer. Radiat Oncol J. 2017;35(3):208\u201316.","journal-title":"Radiat Oncol J"},{"key":"1387_CR44","first-page":"e20210378","volume":"56","author":"LJD Bastos","year":"2022","unstructured":"Bastos LJD, et al. Radiodermatitis: severity, predictive factors and discontinuation of radiotherapy in patients with anal and rectal cancer. Rev Esc Enferm USP. 2022;56:e20210378.","journal-title":"Rev Esc Enferm USP"},{"issue":"4","key":"1387_CR45","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00432-019-02881-8","volume":"145","author":"B De Bari","year":"2019","unstructured":"De Bari B, et al. Neoadjuvant chemoradiotherapy delivered with helical tomotherapy under daily image guidance for rectal cancer patients: efficacy and safety in a large, multi-institutional series. J Cancer Res Clin Oncol. 2019;145(4):1075\u201384.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"14","key":"1387_CR46","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2011.39.6036","volume":"30","author":"A Dewdney","year":"2012","unstructured":"Dewdney A, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). J Clin Oncol. 2012;30(14):1620\u20137.","journal-title":"J Clin Oncol"},{"issue":"6","key":"1387_CR47","doi-asserted-by":"publisher","first-page":"305","DOI":"10.11622\/smedj.2017105","volume":"59","author":"MSF Tseng","year":"2018","unstructured":"Tseng MSF, et al. Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience. Singap Med J. 2018;59(6):305\u201310.","journal-title":"Singap Med J"},{"issue":"8","key":"1387_CR48","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00066-023-02056-y","volume":"199","author":"S Untiedt","year":"2023","unstructured":"Untiedt S, et al. Impact of dose escalation on colostomy-free survival and treatment outcome in squamous cell anal carcinoma. Strahlenther Onkol. 2023;199(8):749\u201360.","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"1387_CR49","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.brachy.2019.08.005","volume":"18","author":"L Varela Cagetti","year":"2019","unstructured":"Varela Cagetti L, et al. High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal Canal cancers. Brachytherapy. 2019;18(6):814\u201322.","journal-title":"Brachytherapy"},{"issue":"2","key":"1387_CR50","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/s10147-013-0567-0","volume":"19","author":"M Morimoto","year":"2014","unstructured":"Morimoto M, et al. Salvage high-dose-rate interstitial brachytherapy for locally recurrent rectal cancer: long-term follow-up results. Int J Clin Oncol. 2014;19(2):312\u20138.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"1387_CR51","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.hemonc.2016.08.004","volume":"9","author":"S Bazarbashi","year":"2016","unstructured":"Bazarbashi S, et al. Pre-operative chemoradiotherapy using capecitabine and cetuximab followed by definitive surgery in patients with operable rectal cancer. Hematol Oncol Stem Cell Ther. 2016;9(4):147\u201353.","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"3","key":"1387_CR52","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/cam4.2722","volume":"9","author":"J Feliu","year":"2020","unstructured":"Feliu J, et al. VITAL phase 2 study: upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal Canal (GEMCAD 09\u2009\u2013\u200902). Cancer Med. 2020;9(3):1008\u201316.","journal-title":"Cancer Med"},{"issue":"4","key":"1387_CR53","first-page":"2027","volume":"36","author":"P Franco","year":"2016","unstructured":"Franco P, et al. Locally advanced (T3-T4 or N+) anal cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy. Anticancer Res. 2016;36(4):2027\u201332.","journal-title":"Anticancer Res"},{"key":"1387_CR54","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/CMAR.S142076","volume":"10","author":"DK Simson","year":"2018","unstructured":"Simson DK, et al. Prospective study of neoadjuvant chemoradiotherapy using intensity-modulated radiotherapy and 5 fluorouracil for locally advanced rectal cancer - toxicities and response assessment. Cancer Manag Res. 2018;10:519\u201326.","journal-title":"Cancer Manag Res"},{"issue":"6","key":"1387_CR55","doi-asserted-by":"publisher","first-page":"522","DOI":"10.5114\/jcb.2018.81025","volume":"10","author":"E Bertin","year":"2018","unstructured":"Bertin E, et al. Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal Canal. J Contemp Brachytherapy. 2018;10(6):522\u201331.","journal-title":"J Contemp Brachytherapy"},{"issue":"1","key":"1387_CR56","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10350-006-0761-5","volume":"50","author":"G Crehange","year":"2007","unstructured":"Crehange G, et al. Combining cisplatin and mitomycin with radiotherapy in anal carcinoma. Dis Colon Rectum. 2007;50(1):43\u20139.","journal-title":"Dis Colon Rectum"},{"key":"1387_CR57","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1186\/s12885-015-1812-x","volume":"15","author":"LH Dr\u00f6ge","year":"2015","unstructured":"Dr\u00f6ge LH, et al. Reduced toxicity in the treatment of locally advanced rectal cancer: a comparison of volumetric modulated Arc therapy and 3D conformal radiotherapy. BMC Cancer. 2015;15:750.","journal-title":"BMC Cancer"},{"issue":"3","key":"1387_CR58","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.brachy.2007.02.152","volume":"6","author":"C Oehler-J\u00e4nne","year":"2007","unstructured":"Oehler-J\u00e4nne C, et al. Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma. Brachytherapy. 2007;6(3):218\u201326.","journal-title":"Brachytherapy"},{"issue":"4","key":"1387_CR59","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1007\/s00066-019-01534-6","volume":"196","author":"M Sauter","year":"2020","unstructured":"Sauter M, et al. Improved treatment outcome and lower skin toxicity with intensity-modulated radiotherapy vs. 3D conventional radiotherapy in anal cancer. Strahlenther Onkol. 2020;196(4):356\u201367.","journal-title":"Strahlenther Onkol"},{"issue":"8","key":"1387_CR60","doi-asserted-by":"publisher","first-page":"e70030","DOI":"10.1111\/iwj.70030","volume":"21","author":"FV Sim\u00f5es","year":"2024","unstructured":"Sim\u00f5es FV, et al. Spray skin protectant versus standard moisturiser in the prevention of radiodermatitis in patients with anal Canal and rectal cancer: A randomised clinical trial. Int Wound J. 2024;21(8):e70030.","journal-title":"Int Wound J"},{"issue":"5","key":"1387_CR61","first-page":"693","volume":"47","author":"V Velenik","year":"2006","unstructured":"Velenik V, et al. Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial. Croat Med J. 2006;47(5):693\u2013700.","journal-title":"Croat Med J"},{"key":"1387_CR62","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2407-11-55","volume":"11","author":"MG Zampino","year":"2011","unstructured":"Zampino MG, et al. Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in Non metastatic anal squamous cell carcinoma. BMC Cancer. 2011;11:55.","journal-title":"BMC Cancer"},{"key":"1387_CR63","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1748-717X-9-70","volume":"9","author":"J Zhu","year":"2014","unstructured":"Zhu J, et al. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II\/III rectal adenocarcinoma: results of a phase II study. Radiat Oncol. 2014;9:70.","journal-title":"Radiat Oncol"},{"issue":"2","key":"1387_CR64","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/jjco\/hym164","volume":"38","author":"SH Lee","year":"2008","unstructured":"Lee SH, et al. Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose. Jpn J Clin Oncol. 2008;38(2):112\u201321.","journal-title":"Jpn J Clin Oncol"},{"issue":"5","key":"1387_CR65","doi-asserted-by":"publisher","first-page":"689","DOI":"10.32604\/or.2023.030351","volume":"31","author":"S Senyurek","year":"2023","unstructured":"Senyurek S, et al. Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4\/N0\u2009+\u2009rectal cancer: Istanbul R-02 phase II randomized study. Oncol Res. 2023;31(5):689\u201396.","journal-title":"Oncol Res"},{"issue":"3","key":"1387_CR66","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1093\/jrr\/rrae019","volume":"65","author":"Y Takagawa","year":"2024","unstructured":"Takagawa Y, et al. Proton beam reirradiation for locally recurrent rectal cancer patients with prior pelvic irradiation. J Radiat Res. 2024;65(3):379\u201386.","journal-title":"J Radiat Res"},{"issue":"12","key":"1387_CR67","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/DCR.0b013e3181ba14ed","volume":"52","author":"A Habr-Gama","year":"2009","unstructured":"Habr-Gama A, et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum. 2009;52(12):1927\u201334.","journal-title":"Dis Colon Rectum"},{"issue":"1","key":"1387_CR68","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s12029-023-00966-9","volume":"55","author":"A Amariyil","year":"2024","unstructured":"Amariyil A, et al. Randomized controlled trial of neoadjuvant Short-Course radiotherapy followed by consolidation chemotherapy versus Long-Course chemoradiotherapy in locally advanced rectal cancer: comparison of overall response rates. J Gastrointest Cancer. 2024;55(1):373\u201382.","journal-title":"J Gastrointest Cancer"},{"issue":"9","key":"1387_CR69","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1007\/PL00002350","volume":"176","author":"J Dunst","year":"2000","unstructured":"Dunst J, et al. Intermittent use of amifostine during postoperative radiochemotherapy and acute toxicity in rectal cancer patients. Strahlenther Onkol. 2000;176(9):416\u201321.","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"1387_CR70","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s13193-012-0181-z","volume":"3","author":"VP Nelamangala Ramakrishnaiah","year":"2012","unstructured":"Nelamangala Ramakrishnaiah VP, et al. Preoperative radiotherapy in carcinoma rectum. Indian J Surg Oncol. 2012;3(4):302\u20137.","journal-title":"Indian J Surg Oncol"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-025-01387-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-025-01387-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:05:21Z","timestamp":1768457121000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12029-025-01387-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1387"],"URL":"https:\/\/doi.org\/10.1007\/s12029-025-01387-6","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"29 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This meta-analysis can provide a strong numerical basis to prevent and treat skin toxicity during radiotherapy among rectoanal cancer patients by determining certain important modified influencing elements, including radiation technology (3D-CRT orvolumetric modulated arc therapy [VMAT]\/intensity-modulated radiotherapy [IMRT]), total dose >50 Gy, and small bowel dosevolume parameter (small bowel volume that receives at least 45 Gy [SBV45Gy] >120 cc)\u2013and showing how effective intervention with spray type skin protectant (Cavilon\u2122),VMAT, HDR-ISBT and amifostine, the results provide risk-stratified, precision-based clinical practice. The obtained dose-response curves and the limits of toxicity (e.g., 50 Gy cumulative) offer actual reference values to optimise RT planning. Multimodality treatment strategies (e.g., VMAT + spray protectant+ amifostine (high risk patients)) may decrease the rate of grade III or higher radiodermatitis and interruption during treatment, improve quality of life, ensure completion and efficacy of radical radiotherapy to enhance overall oncologic outcome.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Translational Relevance"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16"}}